These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 24004830)
1. Comprehensive 3D-QSAR and binding mode of BACE-1 inhibitors using R-group search and molecular docking. Huang D; Liu Y; Shi B; Li Y; Wang G; Liang G J Mol Graph Model; 2013 Sep; 45():65-83. PubMed ID: 24004830 [TBL] [Abstract][Full Text] [Related]
2. Study on the active mechanism of β-secretase inhibitors by molecular simulations. Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel 3,5-bis-N-(aryl/heteroaryl) carbamoyl-4-aryl-1,4-dihydropyridines as small molecule BACE-1 inhibitors. Razzaghi-Asl N; Firuzi O; Hemmateenejad B; Javidnia K; Edraki N; Miri R Bioorg Med Chem; 2013 Nov; 21(22):6893-909. PubMed ID: 24113238 [TBL] [Abstract][Full Text] [Related]
4. A method for induced-fit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors. Moitessier N; Therrien E; Hanessian S J Med Chem; 2006 Oct; 49(20):5885-94. PubMed ID: 17004704 [TBL] [Abstract][Full Text] [Related]
5. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609 [TBL] [Abstract][Full Text] [Related]
6. A PM7 dynamic residue-ligand interactions energy landscape of the BACE1 inhibitory pathway by hydroxyethylamine compounds. Part I: The flap closure process. Gueto-Tettay C; Martinez-Consuegra A; Zuchniarz J; Gueto-Tettay LR; Drosos-Ramírez JC J Mol Graph Model; 2017 Sep; 76():274-288. PubMed ID: 28746905 [TBL] [Abstract][Full Text] [Related]
7. Molecular docking and 3D-QSAR studies on the binding mechanism of statine-based peptidomimetics with beta-secretase. Zuo Z; Luo X; Zhu W; Shen J; Shen X; Jiang H; Chen K Bioorg Med Chem; 2005 Mar; 13(6):2121-31. PubMed ID: 15727865 [TBL] [Abstract][Full Text] [Related]
8. Molecular Docking and 3D Qsar Studies of C000000956 as a Potent Inhibitor of Bace-1. Joseph OA; Babatomiwa K; Niyi A; Olaposi O; Olumide I Drug Res (Stuttg); 2019 Aug; 69(8):451-457. PubMed ID: 30780168 [TBL] [Abstract][Full Text] [Related]
9. Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease. Hossain T; Mukherjee A; Saha A Mol Biosyst; 2015 Feb; 11(2):549-57. PubMed ID: 25435329 [TBL] [Abstract][Full Text] [Related]
10. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β. Kumar A; Srivastava G; Negi AS; Sharma A J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523 [TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. Choi SJ; Cho JH; Im I; Lee SD; Jang JY; Oh YM; Jung YK; Jeon ES; Kim YC Eur J Med Chem; 2010 Jun; 45(6):2578-90. PubMed ID: 20303626 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region. Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903 [TBL] [Abstract][Full Text] [Related]
14. Ensemble-docking approach on BACE-1: pharmacophore perception and guidelines for drug design. Limongelli V; Marinelli L; Cosconati S; Braun HA; Schmidt B; Novellino E ChemMedChem; 2007 May; 2(5):667-78. PubMed ID: 17407105 [TBL] [Abstract][Full Text] [Related]
15. High throughput virtual screening and E-pharmacophore filtering in the discovery of new BACE-1 inhibitors. Muthusamy K; Singh KhD; Chinnasamy S; Nagamani S; Krishnasamy G; Thiyagarajan C; Premkumar P; Anusuyadevi M Interdiscip Sci; 2013 Jun; 5(2):119-26. PubMed ID: 23740393 [TBL] [Abstract][Full Text] [Related]
16. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase. Sauder JM; Arthur JW; Dunbrack RL J Mol Biol; 2000 Jul; 300(2):241-8. PubMed ID: 10873463 [TBL] [Abstract][Full Text] [Related]
17. Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies. John S; Thangapandian S; Sakkiah S; Lee KW BMC Bioinformatics; 2011 Feb; 12 Suppl 1(Suppl 1):S28. PubMed ID: 21342558 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of 2,3,5-substituted imidazolidin-4-one inhibitors of BACE-1. Barrow JC; Rittle KE; Ngo PL; Selnick HG; Graham SL; Pitzenberger SM; McGaughey GB; Colussi D; Lai MT; Huang Q; Tugusheva K; Espeseth AS; Simon AJ; Munshi SK; Vacca JP ChemMedChem; 2007 Jul; 2(7):995-9. PubMed ID: 17458843 [No Abstract] [Full Text] [Related]
19. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease. Semighini EP Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252 [TBL] [Abstract][Full Text] [Related]
20. [Application of an R-group search strategy into three-dimensional quantitative structure-activity relationship of HEA beta-secretase inhibitors and molecular virtual screening]. Shi B; Liu Y; Li Y; Wang G; Liang G Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Feb; 31(1):196-204. PubMed ID: 24804511 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]